Evidence map›Paper›PMID 42239266›Full record

ArticlebioRxiv : the preprint server for biology2026

Zuranolone mitigates delirium-like bispectral EEG changes, behavioral deficits, and neuroinflammation across surgical and inflammatory mouse models and age groups.

Bun Aoyama, Shota Nishitani, Kyosuke Yamanishi, Hieu D Nguyen, Rika Sakuma, Takaya Ishii, Yukiko Ikeda, Tsuyoshi Nishiguchi, Ilgin Genc, Nathan J Phuong and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bun AoyamaDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.ORCID 0000-0001-6330-7622
Shota NishitaniDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Kyosuke YamanishiDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Hieu D NguyenDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Rika SakumaDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Takaya IshiiDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Yukiko IkedaDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Tsuyoshi NishiguchiDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Ilgin GencDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Nathan J PhuongDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Nipun GorantlaDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Tomoteru SekiDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Akiyoshi ShimuraDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Takashi KawanoDepartment of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Nankoku, Kochi, Japan.
Gen ShinozakiDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.

Funding

Epigenetics Biomarker of Post Operative Delirium and Long Term Cognitive Decline among Elderly Dementia PatientsR01AG084710 · NIA · STANFORD UNIVERSITY · PI Gen Shinozaki · 2024 to 2026
$3.4M
Identification of Epigenetics Correlates between Brain and Peripheral TissuesR01MH119165 · NIMH · UNIVERSITY OF IOWA · PI SHINOZAKI, GEN · 2020 to 2024
$3.0M
NIA NIH HHS R01 AG084710NIMH NIH HHS R01 MH119165
6 · The paper itself

Abstract

Delirium is an acute, fluctuating brain dysfunction that commonly follows surgery and systemic inflammation, disproportionately affects older adults, and remains difficult to quantify continuously over time and treat pharmacologically. Here, we tested whether the neuroactive steroid zuranolone, a positive allosteric modulator of synaptic and extrasynaptic GABA_A receptors, mitigates delirium-like abnormalities across two complementary murine delirium models, a lipopolysaccharide-induced systemic inflammation (LPS) model and a postoperative delirium (POD) model, primarily in young and aged mice, with selected analyses in super-aged mice. Using continuous EEG with a validated bispectral EEG (BSEEG) metric, we found that zuranolone attenuated delirium-like EEG slowing in the LPS model in young mice in a dose-dependent manner and retained efficacy in aged mice. In the POD model, prophylactic dosing provided limited benefit in young mice, whereas post-surgery treatment reduced postoperative BSEEG elevations. In aged mice, prophylactic dosing suppressed POD-associated BSEEG abnormalities, and in super-aged mice, prophylactic zuranolone improved survival after POD induction. In parallel, zuranolone reduced microglial density and activation markers (IBA1 and CD68 immunoreactivity) at 24 h after POD surgery and after LPS challenge, with effects that were particularly evident in peri-screw site tissue in young POD mice and more broadly distributed across regions in aged mice. Finally, in young mice, zuranolone improved a composite behavioral severity score in the LPS model, whereas behavioral effects in the POD model were modest and domain-specific. Together, these findings support zuranolone as a candidate strategy to reduce delirium-like electrophysiological and neuroimmune abnormalities, with the strongest effects in inflammation-driven and age-vulnerable contexts.

Identifiers

PMID42239266
PMCPMC13228380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.